{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:42:31Z","timestamp":1793763751886,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:20:55Z","timestamp":1768062055000},"page":"623.e1-623.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review\/Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Armin","family":"Ghobadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2142-7356","authenticated-orcid":false,"given":"Theodora","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-7813","authenticated-orcid":false,"given":"Matthew","family":"Ulrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-8991","authenticated-orcid":false,"given":"Zhen-Huan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Scott","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2026.01.010_bib0001","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.010_bib0002","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41375-020-0963-1","article-title":"Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review","volume":"34","author":"Zhu","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2026.01.010_bib0003","first-page":"1","article-title":"Endpoints in oncology clinical trials","volume":"23","author":"Kilickap","year":"2018","journal-title":"J BUON"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.010_bib0004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2026.01.010_bib0005","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.01.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103711","article-title":"Validity of event-free survival as a surrogate endpoint in haematological malignancy: review of the literature and health technology assessments","volume":"175","author":"Assouline","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2026.01.010_bib0007","unstructured":"YESCARTA \u00ae (axicabtagene ciloleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc.; 2025."},{"issue":"1","key":"10.1016\/j.jtct.2026.01.010_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2026.01.010_bib0009","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2026.01.010_bib0010","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jtct.2026.01.010_bib0011","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.010_bib0012","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.010_bib0013","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","article-title":"Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies","volume":"20","author":"Ayers","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"10.1016\/j.jtct.2026.01.010_bib0014","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.01.010_bib0015","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.010_bib0016","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.010_bib0017","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.010_bib0018","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.01.010_bib0019","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.010_bib0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2023020984","article-title":"Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy","volume":"143","author":"Bommier","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.010_bib0021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.01.010_bib0022","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/neuonc\/noq010","article-title":"Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma","volume":"12","author":"Pels","year":"2010","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.010_bib0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/oncolo\/oyac006","article-title":"Surrogacy beyond prognosis: the importance of \u201cTrial-Level\u201d surrogacy","volume":"27","author":"Buyse","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2026.01.010_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:06:57Z","timestamp":1780312017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636726000229"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review\/Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}